Optura Raises $17.5M to Scale ROAI Platform

Optura announced a $17.5 million Series A round led by Salesforce Ventures, with participation from Echo Health Ventures and continued investment from Susa Ventures, Matrix Partners, and HC9 Ventures, bringing total capital raised to over $25 million, per a PR Newswire distribution published May 14, 2026 and subsequent reporting in FierceHealthcare and Healthcare IT Today. The PR release attributes operational metrics to Optura including generating over $120M in value, achieving 700% ROAI for in-flight initiatives, and documenting more than 250 use cases across multi-million-dollar healthcare organizations (PR Newswire; FierceHealthcare).

Per the PR materials, Optura offers an enterprise platform that it frames as delivering ROAI (Return on AI Investment) by enabling organizations to assess business value, prioritize AI investments, and track enterprise impact and return in real time. The public announcement includes direct quotes from Optura co-founder and CEO Andy Fanning describing the proliferation of point solutions and the need for an "objective framework" to measure AI returns, and a quote from Katie Thiry, Managing Director at Salesforce Ventures, which calls for greater rigor and visibility in AI investment decisions (PR Newswire).

Editorial analysis: Healthcare saw concentrated AI investment in 2025, with industry reporting that AI-related healthcare deals represented a large share of sector funding - reports cited in coverage include a 2025 figure that AI healthcare investments represented 46% of total healthcare spending on startups, and academic work indicating high rates of generative AI pilots without measurable ROI (FierceHealthcare; MIT NANDA cited in coverage). Companies and investors highlighted in the coverage frame Optura's proposition as targeting that measurement gap.

Editorial analysis: For data science and ML teams inside health plans and provider systems, tools that translate model outputs into measurable financial and operational KPIs address a recurrent adoption barrier: models that perform technically but fail to deliver tracked business impact. The pitch from Optura, as presented in public materials, centers on mapping AI use cases to enterprise KPIs and monitoring realized value-functions that typically require productized pipelines for data integration, change-tracking, A/B or counterfactual measurement, and governance metadata.

Editorial analysis: Observers should track three signals:

• •customer list expansion and case study depth beyond the named early accounts reported in press coverage, which will reveal whether ROAI measures generalize across payer and provider contexts
• •technical integrations with clinical, claims, or care-management data systems and whether Optura publishes methodological details on attribution and measurement approaches
• •investor and partner activity - strategic investor involvement may enable enterprise channel and partner integrations; watch for partner announcements and go-to-market motions (Echo Health Ventures; Salesforce Ventures commentary in coverage)

Optura's Series A, led by a strategic investor with enterprise cloud reach, signals continued investor interest in startups that aim to operationalize AI ROI measurement in healthcare. The funding and the metrics cited in the PR release position the company as part of a wave of vendors selling measurement and governance tooling rather than base models or point solutions.